Literature DB >> 17298650

Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes.

Vincenzo Guadagnino1, Maria Paola Trotta, Franco Montesano, Sergio Babudieri, Benedetto Caroleo, Orlando Armignacco, Jessica Carioti, Giuseppe Maio, Roberto Monarca, Andrea Antinori.   

Abstract

AIM: To evaluate the effect of a multi-disciplinary standardized management model on the efficacy of pegylated (Peg)-interferon alpha-2b plus ribavirin treatment of chronic hepatitis C in drug addicts undergoing substitutive or antagonist therapy.
DESIGN: Observational prospective multi-centre study.
SETTING: Six clinical infectious disease centres in collaboration with 11 drug dependency units (DDU) in five Italian regions. PARTICIPANTS: Intravenous drug users affected by chronic hepatitis C engaged in detoxification programmes.
METHODS: Application of a multi-disciplinary standardized management model for HCV treatment involving DDU operators, psychologists or psychiatrists and infectious disease specialists. MEASUREMENTS: Very early, early, end-of-treatment and sustained virological response to Peg-interferon alpha-2b plus ribavirin.
FINDINGS: Fifty-three subjects were studied [43.4% with hepatitis C virus (HCV) genotypes 1 or 4]. Intent-to-treat analysis showed an end-of-treatment virological response in 58.5% of patients (39.1% genotypes 1 or 4; 73.4% genotype 3) and a sustained virological response in 54.7% (34.8% genotypes 1 or 4; 70.0% genotype 3). There were 19 (35.8%) dropouts and three (5.7%) non-responders: one genotype 1 and two genotype 4. Two (3.8%) patients relapsed: genotypes 1 and 3. On-treatment analysis showed negative HCV-RNA in 40 (93.1%) of 43 subjects who completed the first 12 treatment weeks and in 35 who completed the first 24 treatment weeks. All subjects with an end-of-treatment response, except one with genotype 3 infection, had a sustained response.
CONCLUSIONS: Our data show that antiviral treatment in the context of a multi-disciplinary standardized management model helps many HCV-positive drug addicts achieve a good virological response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17298650     DOI: 10.1111/j.1360-0443.2006.01698.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  14 in total

Review 1.  Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Authors:  Amber Arain; Geert Robaeys
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

2.  Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.

Authors:  Melissa R Stein; Irene J Soloway; Karen S Jefferson; Robert J Roose; Julia H Arnsten; Alain H Litwin
Journal:  J Subst Abuse Treat       Date:  2012-10-02

Review 3.  Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.

Authors:  Rositsa B Dimova; Marija Zeremski; Ira M Jacobson; Holly Hagan; Don C Des Jarlais; Andrew H Talal
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

4.  Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Authors:  Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2015-07-17

5.  Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre.

Authors:  Adam Isaiah Newman; Shelley Beckstead; David Beking; Susan Finch; Tina Knorr; Carol Lynch; Meredith MacKenzie; Daphne Mayer; Brenda Melles; Ron Shore
Journal:  Can J Gastroenterol       Date:  2013-04       Impact factor: 3.522

6.  Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre.

Authors:  Joseph Moussalli; Helene Delaquaize; Dominique Boubilley; Jean Pierre Lhomme; Jules Merleau Ponty; David Sabot; Anne Kerever; Marc Valleur; Thierry Poynard
Journal:  Gastroenterol Res Pract       Date:  2010-07-18       Impact factor: 2.260

7.  Addicts with chronic hepatitis C: difficult to reach, manage or treat?

Authors:  Barbara Zanini; Federica Benini; Marie Graciella Pigozzi; Patrizia Furba; Ernesto Giacò; Antonia Cinquegrana; Mariagrazia Fasoli; Alberto Lanzini
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

Review 8.  Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research.

Authors:  J J Weiss; N Bräu; A Stivala; T Swan; D Fishbein
Journal:  Aliment Pharmacol Ther       Date:  2009-03-26       Impact factor: 8.171

9.  The high comorbidity burden of the hepatitis C virus infected population in the United States.

Authors:  Karly S Louie; Samantha St Laurent; Ulla M Forssen; Linda M Mundy; Jeanne M Pimenta
Journal:  BMC Infect Dis       Date:  2012-04-11       Impact factor: 3.090

Review 10.  Bloodborne viral hepatitis infections among drug users: the role of vaccination.

Authors:  Fabio Lugoboni; Gianluca Quaglio; Paolo Civitelli; Paolo Mezzelani
Journal:  Int J Environ Res Public Health       Date:  2009-01-22       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.